S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
This Tech Stock Could be the Next Amazon (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
3 Secrets To Consistent Trading Success (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
3 Secrets To Consistent Trading Success (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
This Tech Stock Could be the Next Amazon (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
3 Secrets To Consistent Trading Success (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
3 Secrets To Consistent Trading Success (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
This Tech Stock Could be the Next Amazon (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
3 Secrets To Consistent Trading Success (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
3 Secrets To Consistent Trading Success (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
This Tech Stock Could be the Next Amazon (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
3 Secrets To Consistent Trading Success (Ad)pixel
UN body mulls deep sea mining amid demand for minerals
Intensity and insults rise as lawmakers debate debt ceiling
3 Secrets To Consistent Trading Success (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Canada approves largest telecom deal in country's history
NASDAQ:KNSA

Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

$10.76
+0.06 (+0.56%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.64
$11.04
50-Day Range
$10.70
$14.52
52-Week Range
$7.36
$17.19
Volume
800,250 shs
Average Volume
459,650 shs
Market Capitalization
$750.51 million
P/E Ratio
4.15
Dividend Yield
N/A
Price Target
$20.00

Kiniksa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
85.9% Upside
$20.00 Price Target
Short Interest
Healthy
3.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.40mentions of Kiniksa Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

87th out of 1,004 stocks

Pharmaceutical Preparations Industry

31st out of 489 stocks


KNSA stock logo

About Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Stock News Headlines

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Down 3.9%
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
The Top 7 Growth Stocks in Biotech
Earnings Scheduled For February 28, 2023
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
KNSA Kiniksa Pharmaceuticals, Ltd.
Recap: Kiniksa Pharmaceuticals Q3 Earnings
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Company Calendar

Last Earnings
11/01/2021
Today
4/01/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+85.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$183.36 million
Pretax Margin
5.01%

Debt

Sales & Book Value

Annual Sales
$220.18 million
Cash Flow
$2.57 per share
Book Value
$5.68 per share

Miscellaneous

Free Float
31,689,000
Market Cap
$750.51 million
Optionable
Not Optionable
Beta
-0.07

Key Executives

  • Sanj K. Patel
    Chairman & Chief Executive Officer
  • Eben P. Tessari
    Chief Operating Officer & Senior Vice President
  • Mark Ragosa
    Chief Financial Officer & Senior Vice President
  • John F. Paolini
    Chief Medical Officer & Senior Vice President
  • Chad Morin
    Chief Compliance Officer & Vice President













KNSA Stock - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price forecast for 2023?

1 analysts have issued 1 year target prices for Kiniksa Pharmaceuticals' shares. Their KNSA share price forecasts range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2023?

Kiniksa Pharmaceuticals' stock was trading at $14.98 at the beginning of 2023. Since then, KNSA shares have decreased by 28.2% and is now trading at $10.76.
View the best growth stocks for 2023 here
.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 2,520,000 shares, a decline of 7.4% from the February 28th total of 2,720,000 shares. Based on an average daily trading volume, of 374,600 shares, the short-interest ratio is currently 6.7 days.
View Kiniksa Pharmaceuticals' Short Interest
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our KNSA earnings forecast
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 83.28% and a trailing twelve-month return on equity of 2.18%.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $10.76.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $750.51 million and generates $220.18 million in revenue each year. The company earns $183.36 million in net income (profit) each year or $2.59 on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

The company employs 215 workers across the globe.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com.

This page (NASDAQ:KNSA) was last updated on 4/1/2023 by MarketBeat.com Staff